{"related:f7Oeq0U9tJYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Safety, activity, and immune correlates of anti–PD-1 antibody in cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","authors":["SL Topalian","SL Topalian FS Hodi","SL Topalian FS Hodi JR Brahmer…"],"year":2012,"numCitations":9272,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","citationUrl":"http://scholar.google.com/scholar?cites=10859371970938450815&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:f7Oeq0U9tJYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10859371970938450815&hl=en&as_sdt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596365389223},{"title":"Safety and activity of anti–PD-L1 antibody in patients with advanced cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","authors":["JR Brahmer","JR Brahmer SS Tykodi","JR Brahmer SS Tykodi LQM Chow…"],"year":2012,"numCitations":5905,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","citationUrl":"http://scholar.google.com/scholar?cites=13360512895833832804&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZH0zFbETarkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13360512895833832804&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Improved survival with ipilimumab in patients with metastatic melanoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1003466","authors":["FS Hodi","FS Hodi SJ O'Day","FS Hodi SJ O'Day DF McDermott…"],"year":2010,"numCitations":12005,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1003466","citationUrl":"http://scholar.google.com/scholar?cites=2675556821352765108&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:tNYa2cB8ISUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2675556821352765108&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","authors":["O Hamid","O Hamid C Robert","O Hamid C Robert A Daud","O Hamid C Robert A Daud FS Hodi…"],"year":2013,"numCitations":3154,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","citationUrl":"http://scholar.google.com/scholar?cites=164069860268346458&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WoykK6vkRgIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=164069860268346458&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"The blockade of immune checkpoints in cancer immunotherapy","url":"https://www.nature.com/articles/nrc3239/","authors":["DM Pardoll"],"year":2012,"numCitations":7743,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4856023/","citationUrl":"http://scholar.google.com/scholar?cites=11484971735372092127&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:31JBfvHQYp8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11484971735372092127&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Nivolumab plus ipilimumab in advanced melanoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1302369","authors":["JD Wolchok","JD Wolchok H Kluger","JD Wolchok H Kluger MK Callahan","JD Wolchok H Kluger MK Callahan MA Postow…"],"year":2013,"numCitations":3707,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1302369","citationUrl":"http://scholar.google.com/scholar?cites=14171047859475257990&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:hhoVX_KsqcQJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14171047859475257990&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4834717/","authors":["JR Brahmer","JR Brahmer CG Drake","JR Brahmer CG Drake I Wollner…"],"year":2010,"numCitations":2416,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4834717/","citationUrl":"http://scholar.google.com/scholar?cites=10977515176452218091&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:69zkQOT3V5gJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10977515176452218091&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","url":"https://www.nature.com/articles/nature14011?page=1","authors":["RS Herbst","RS Herbst JC Soria","RS Herbst JC Soria M Kowanetz","RS Herbst JC Soria M Kowanetz GD Fine","RS Herbst JC Soria M Kowanetz GD Fine O Hamid…"],"year":2014,"numCitations":3074,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4836193/","citationUrl":"http://scholar.google.com/scholar?cites=16172811975131816039&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Z2Dq3M1eceAJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16172811975131816039&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","url":"https://www.nature.com/articles/nm730","authors":["H Dong","H Dong SE Strome","H Dong SE Strome DR Salomao","H Dong SE Strome DR Salomao H Tamura…"],"year":2002,"numCitations":4147,"pdf":"https://www.researchgate.net/profile/Esteban_Celis/publication/298204392_Tumor-associated_B7-H1_promotes_T-cell_apoptosis_A_potential_mechanism_of_immune_evasion_vol_8_pg_793_2002/links/5d03e626a6fdcc39f11b5963/Tumor-associated-B7-H1-promotes-T-cell-apoptosis-A-potential-mechanism-of-immune-evasion-vol-8-pg-793-2002.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16232844485483822153&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Sfxr4w2mRuEJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16232844485483822153&hl=en&as_sdt=0,5","publication":"nature.com"},{"title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","url":"https://www.nejm.org/doi/full/10.1056/Nejmoa1104621","authors":["C Robert","C Robert L Thomas","C Robert L Thomas I Bondarenko…"],"year":2011,"numCitations":4204,"pdf":"https://www.nejm.org/doi/full/10.1056/Nejmoa1104621","citationUrl":"http://scholar.google.com/scholar?cites=12343025222570741636&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:hA8ENQs8S6sJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12343025222570741636&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"}]}